KCI dient registratie in voor voorgestelde eerste openbare aanbieding
SAN ANTONIO–(BUSINESS WIRE)–Acelity heeft vandaag aangekondigd dat haar gelieerde onderneming, KCI Holdings, Inc. (“KCI”), een registratieverklaring op formulier S-1 heeft ingediend bij de Amerikaanse Securities and Exchange Commission (“SEC”), met betrekking tot een voorgestelde beursintroductie van KCI’s gewone aandelen. Voordat de registratieverklaring effectief is, zal er een herstructurering plaatsvinden. Daar zal KCI de holdingmaatschappij worden van de activiteiten die momenteel worden uitgevoerd door Acelity L.P. Inc. en haar dochterondernemingen. Het aantal aandelen dat wordt aangeboden en de prijsklasse voor het voorgestelde aanbod zijn nog niet vastgesteld.
J.P. Morgan, Goldman Sachs & Co. LLC en BofA Merrill Lynch treden op als joint book-running managers voor het voorgestelde aanbod.
KCI Files Registration Statement for Proposed Initial Public Offering
SAN ANTONIO–(BUSINESS WIRE)– Acelity announced today that its affiliate, KCI Holdings, Inc. (“KCI”), filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”), relating to a proposed initial public offering of KCI’s common stock. Prior to the effectiveness of the registration statement, there will be a restructuring as a result of which KCI will become the holding company of the businesses currently conducted by Acelity L.P. Inc. and its subsidiaries. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
J.P. Morgan, Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from: J.P. Morgan, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 1-866-803-9204; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: 1-866-471-2526 or by facsimile at 212-902-9316, or via email: prospectus-ny@ny.email.gs.com; or BofA Merrill Lynch, Attn: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@baml.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Acelity
Acelity L.P. Inc. is a global medical technology company focused on advanced wound care and specialty surgical applications marketed under the KCI brand. The KCI product portfolio is available in more than 90 countries. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005387/en/
Contacts
Maggie Fairchild
Corporate Communications, Media
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com
David Clair, CFA
Investor Relations
Westwicke Partners
Phone: +1-646-277-1266
Email: investors@acelity.com